Mutations conferring foscamet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis

Adriana Weinberg, Douglas A. Jabs, Sunwen Chou, Barbara K. Martin, Nell S. Lurain, Michael S. Forman, Clyde Crumpacker

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

The dinical significance of cytomegalovirus (CMV) foscarnet resistance was studied in patients with acquired immunodeficiency syndrome and CMV retinitis. Sequencing of the CMV pol gene was performed in 30 isolates. Phenotypic resistance was characterized by the DNA hybridization assay (DHA) in 30 isolates and by plaque-reduction assay (PRA) in 18 isolates. Nine isolates had foscarnet resistance mutations, including V787L and E756Q that were confirmed by marker transfer experiments. Seven of 9 isolates with a 50% inhibitory concentration (IC50) >600 μM by DHA had genotypic resistance, compared with 2 of 21 with an IC50 ≤600 μM (P = .0005). By PRA, 5 isolates had an IC50 >400 μM and genotypic resistance, whereas only 1 of 13 susceptible isolates had genotypic resistance (P = .0007). Sixteen of 18 isolates had concordant PRA and DHA phenotypes. Among 44 patients treated with foscarnet, drug resistance increased the risk of retinitis progression (odds ratio, 14; P = .016). The incidence of foscarnet resistance after 6, 9, and 12 months of therapy was 13%, 24%, and 37%, respectively.

Original languageEnglish (US)
Pages (from-to)777-784
Number of pages8
JournalJournal of Infectious Diseases
Volume187
Issue number5
DOIs
StatePublished - Mar 1 2003

Fingerprint

Cytomegalovirus Retinitis
Foscarnet
Inhibitory Concentration 50
Acquired Immunodeficiency Syndrome
Mutation
Cytomegalovirus
DNA
pol Genes
Retinitis
Dizziness
Drug Resistance
Odds Ratio
Phenotype
Incidence

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Mutations conferring foscamet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. / Weinberg, Adriana; Jabs, Douglas A.; Chou, Sunwen; Martin, Barbara K.; Lurain, Nell S.; Forman, Michael S.; Crumpacker, Clyde.

In: Journal of Infectious Diseases, Vol. 187, No. 5, 01.03.2003, p. 777-784.

Research output: Contribution to journalArticle

Weinberg, Adriana ; Jabs, Douglas A. ; Chou, Sunwen ; Martin, Barbara K. ; Lurain, Nell S. ; Forman, Michael S. ; Crumpacker, Clyde. / Mutations conferring foscamet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. In: Journal of Infectious Diseases. 2003 ; Vol. 187, No. 5. pp. 777-784.
@article{440f9673c23940059699269cdd8a06a0,
title = "Mutations conferring foscamet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis",
abstract = "The dinical significance of cytomegalovirus (CMV) foscarnet resistance was studied in patients with acquired immunodeficiency syndrome and CMV retinitis. Sequencing of the CMV pol gene was performed in 30 isolates. Phenotypic resistance was characterized by the DNA hybridization assay (DHA) in 30 isolates and by plaque-reduction assay (PRA) in 18 isolates. Nine isolates had foscarnet resistance mutations, including V787L and E756Q that were confirmed by marker transfer experiments. Seven of 9 isolates with a 50{\%} inhibitory concentration (IC50) >600 μM by DHA had genotypic resistance, compared with 2 of 21 with an IC50 ≤600 μM (P = .0005). By PRA, 5 isolates had an IC50 >400 μM and genotypic resistance, whereas only 1 of 13 susceptible isolates had genotypic resistance (P = .0007). Sixteen of 18 isolates had concordant PRA and DHA phenotypes. Among 44 patients treated with foscarnet, drug resistance increased the risk of retinitis progression (odds ratio, 14; P = .016). The incidence of foscarnet resistance after 6, 9, and 12 months of therapy was 13{\%}, 24{\%}, and 37{\%}, respectively.",
author = "Adriana Weinberg and Jabs, {Douglas A.} and Sunwen Chou and Martin, {Barbara K.} and Lurain, {Nell S.} and Forman, {Michael S.} and Clyde Crumpacker",
year = "2003",
month = "3",
day = "1",
doi = "10.1086/368385",
language = "English (US)",
volume = "187",
pages = "777--784",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Mutations conferring foscamet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis

AU - Weinberg, Adriana

AU - Jabs, Douglas A.

AU - Chou, Sunwen

AU - Martin, Barbara K.

AU - Lurain, Nell S.

AU - Forman, Michael S.

AU - Crumpacker, Clyde

PY - 2003/3/1

Y1 - 2003/3/1

N2 - The dinical significance of cytomegalovirus (CMV) foscarnet resistance was studied in patients with acquired immunodeficiency syndrome and CMV retinitis. Sequencing of the CMV pol gene was performed in 30 isolates. Phenotypic resistance was characterized by the DNA hybridization assay (DHA) in 30 isolates and by plaque-reduction assay (PRA) in 18 isolates. Nine isolates had foscarnet resistance mutations, including V787L and E756Q that were confirmed by marker transfer experiments. Seven of 9 isolates with a 50% inhibitory concentration (IC50) >600 μM by DHA had genotypic resistance, compared with 2 of 21 with an IC50 ≤600 μM (P = .0005). By PRA, 5 isolates had an IC50 >400 μM and genotypic resistance, whereas only 1 of 13 susceptible isolates had genotypic resistance (P = .0007). Sixteen of 18 isolates had concordant PRA and DHA phenotypes. Among 44 patients treated with foscarnet, drug resistance increased the risk of retinitis progression (odds ratio, 14; P = .016). The incidence of foscarnet resistance after 6, 9, and 12 months of therapy was 13%, 24%, and 37%, respectively.

AB - The dinical significance of cytomegalovirus (CMV) foscarnet resistance was studied in patients with acquired immunodeficiency syndrome and CMV retinitis. Sequencing of the CMV pol gene was performed in 30 isolates. Phenotypic resistance was characterized by the DNA hybridization assay (DHA) in 30 isolates and by plaque-reduction assay (PRA) in 18 isolates. Nine isolates had foscarnet resistance mutations, including V787L and E756Q that were confirmed by marker transfer experiments. Seven of 9 isolates with a 50% inhibitory concentration (IC50) >600 μM by DHA had genotypic resistance, compared with 2 of 21 with an IC50 ≤600 μM (P = .0005). By PRA, 5 isolates had an IC50 >400 μM and genotypic resistance, whereas only 1 of 13 susceptible isolates had genotypic resistance (P = .0007). Sixteen of 18 isolates had concordant PRA and DHA phenotypes. Among 44 patients treated with foscarnet, drug resistance increased the risk of retinitis progression (odds ratio, 14; P = .016). The incidence of foscarnet resistance after 6, 9, and 12 months of therapy was 13%, 24%, and 37%, respectively.

UR - http://www.scopus.com/inward/record.url?scp=0037332358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037332358&partnerID=8YFLogxK

U2 - 10.1086/368385

DO - 10.1086/368385

M3 - Article

VL - 187

SP - 777

EP - 784

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 5

ER -